Thu, Nov 27, 2014, 11:22 AM EST - U.S. Markets closed for Thanksgiving Day

Recent

% | $
Quotes you view appear here for quick access.

Ligand Pharmaceuticals Incorporated Message Board

  • kmallstar kmallstar Jan 17, 2013 4:32 PM Flag

    Onyx raised money...

    ...to buy LGND. Pure speculation, but:

    Onyx Pharmaceuticals Inc. said Wednesday that it expects its stock sale will generate gross proceeds of $358.6 million, which it will use for cancer drug research and development and to help market its drug Kyprolis.

    The company is offering 4.4 million shares of its common stock, and has granted underwriters the option to buy another 660,000 shares if demand exceeds initial supply. The projection would estimate a sale price of about $81.50 each.

    Kyprolis is an injectable drug approved as a treatment for multiple myeloma, a type of cancer that causes tumors to grow in the bone marrow, preventing the production of normal blood cells. The FDA approved Kyprolis on July 20, allowing Onyx to market it for use in patients who have already been treated with at least two other multiple myeloma drugs without success.

    Onyx also has developed a colorectal cancer pill with Bayer, called Stivarga, and developed Nexavar, which is used to treat liver and kidney cancer.

    The company said the offering is expected to close on or about January 22. BofA Merrill Lynch and Barclays are acting as joint book-running managers for this offering.

    Shares of the South San Francisco-based company fell nearly 5 percent to $79.29 in afternoon trading on three times average daily trading volume.

 
LGND
53.70-0.290(-0.54%)Nov 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
SeaDrill Limited
NYSEWed, Nov 26, 2014 4:01 PM EST
AGCO Corporation
NYSEWed, Nov 26, 2014 4:05 PM EST